Abbott’s Navitor approved by FDA for aortic stenosis

Abbott announced that the FDA has approved the company’s latest-generation transcatheter aortic valve implantation – TAVI – system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. The Navitor TAVI system is the latest addition to the company’s transcatheter structural heart portfolio. For patients with severe aortic stenosis who are at high or extreme surgical risk due to the potential complications stemming from age, frailty, or having multiple other diseases or conditions, physicians may opt for a minimally invasive procedure using TAVI therapies such as the Navitor system.The Navitor device is implanted using Abbott’s FlexNav delivery system.